eIF3a-C predict benefit from CT treatment (validation cohort).

a<p>: Log-rank method <i>P</i><0.05 was considered statistically significant.</p><p>CI: confidence interval.</p

Patients Characteristics And Biomarkers (research cohort n = 537).

a<p>: Chemotherapy data of 18 patients in research cohort were missed.</p>b<p>: Chi-square test, <i>P</i><0.01 was considered statistically significant (2-tailed).</p

Predictive analyses according to CT treatment and eIF3a, p27 status.

<p><b>A.</b> DFS curve of high eIF3a-C subgroup stratified by CT treatment in stage II patients of research cohort (n = 119). B. DSS curve of high eIF3a-C subgroup according to CT treatment in validation cohort (n = 192). C. DSS of low p27-N subgroup according to CT treatment in validation cohort (n = 212). D. DSS of high eIF3a-C and low p27-N subgroup according to CT treatment in validation cohort (n = 91).</p

Prognostic analyses according to the expression of eIF3a, p27 status.

<p>A. Kaplan-Meier estimates of the probability of DSS according to eIF3a-N (research cohort, n = 537); B. DSS curves according to p27-N(research cohort, n = 537); C. DSS curve according to combination of high eIF3a-N and p27-N(research cohort, n = 537). D. DFS curve of stage I NSCLC according to p27-C in research cohort (n = 168).</p

Representative images of eIF3a and p27.

<p>A. positive cytoplasmic with negative nuclear staining of eIF3a; B. positive nuclear with negative cytoplasmic staining of eIF3a; C. positive cytoplasmic with negative nuclear staining of p27; D. positive nuclear with negative cytoplasmic staining of p27; Positive nuclear with negative cytoplasmic staining of eIF3a (E) and p27 (F). Positive staining of both cytoplasmic and nuclear eIF3a (G) and p27 (H). (Magnification: 200 for all images).</p

Predictive Analyses Of Validation Cohort (n = 439).

a<p>: Univariate analysis (Log-rank method); <i>P</i><0.05 was considered statistically significant.</p>b<p>: Multivariate analysis (Cox proportional hazard model), <i>P</i><0.05 was considered statistically significant.</p><p>Abbreviation: HR: hazard ratio; CI: confidence interval.</p

Distribution of subcellular eIF3a and p27.

<p>A Distribution of IHC scores in research cohort. (○) Outliers (*) Extremes. B Distribution of p27-C according to eIF3a-C status; chi-squaer test: <i>P</i><0.001. C Distribution of p27-N according to eIF3a-N status;chi-squaer test: <i>P</i><0.001.</p

Telmisartan PKs of 48 health males with different genotypes.

<p>Data were shown as mean±SD;</p>*<p><i>P</i><0.05; **<i>P</i><0.01.</p><p>PKs, pharmacokinetics; <i>ORM1</i>, orosomucoid 1; <i>ABCC2</i>, ATP-binding cassette, sub-family C, member 2; <i>ABCG2</i>, ATP-binding cassette, sub-family G, member 2; <i>ABCB1,</i> ATP-binding cassette, sub-family B, member 1; <i>SLCO1B3,</i> solute carrier organic anion transporter family, member 1B3; SNP, single nucleotide polymorphisms; AUC_(0–48) the area under the plasma concentration-time curve (AUC) from 0 to 48 h; AUC_(0–∞), AUC from 0 to ∞; C_max, the peak concentration in plasma; CL/F, clearance; T_1/2, elimination half-life; T_max, the time to C_max.</p

Summary of Genetic Variations of SNPs in this Study.

a<p>data published on hapmap; b, data calculated in this study, N = 48; N/A, no data found in hapmap.</p><p>MAF: Minor Allele frequencies; CHB: Han Chinese in Beijing, China; ASW: African ancestry in Southwest USA; CEU: Utah residents with Northern and Western European ancestry from the CEPH collection <i>ORM1</i>, orosomucoid 1; <i>ABCC2</i>, ATP-binding cassette, sub-family C, member 2; <i>ABCG2</i>, ATP-binding cassette, sub-family G, member 2; <i>ABCB1,</i> ATP-binding cassette, sub-family B, member 1; <i>SLCO1B3,</i> solute carrier organic anion transporter family, member 1B3; SNP, single nucleotide polymorphisms; AUC_(0–48) the area under the plasma concentration-time curve (AUC) from 0 to 48 h; AUC_(0–∞), AUC from 0 to ∞; C_max, the peak concentration in plasma; CL/F, clearance; T_1/2, elimination half-life; T_max, the time to C_max.</p

The demographics information of the participants.

<p>BMI, body mass index.</p